🇺🇸 FDA

Company profile · Sponsor

Prelude

Prelude Therapeutics Inc

PRLD · NYSE pharma WILMINGTON, DE, USA
Pipeline
13
Drugs
0
Patents
8

Quick answer

Prelude (PRLD) is a pharma company. headquartered in WILMINGTON, DE, USA. listed on NYSE. NovaPharmaNews links 13 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker PRLD
Exchange NYSE
Company type pharma
Headquarters WILMINGTON, DE, USA
SEC CIK 0001678660

Pipeline (13)

Search pipeline →

  1. KEYTRUDA 25 mg/mL concentrate for solution for infusion, PRT3789

    Prelude

    non-small cell lung cancer (NSCLC), Esophageal Cancer, Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

    phase 2 small molecule active

    1 trial

  2. PRT3789

    Prelude

    Advanced Solid Tumor

    phase 2 small molecule completed

    2 trials

  3. A Phase 1 Study of PRT7732, an Oral SMARCA2 Degrader, in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

    Prelude

    esophageal, gastric, or gastroesophageal junction adenocarcinoma, esophageal, gastric, or gastroesophageal junction squamous cell carcinoma, Non-small cell lung cancer (NSCLC), Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

    phase 1 other active

    1 trial

  4. PRT12396

    Prelude

    Polycythemia Vera (PV)

    phase 1 small molecule active

    1 trial

  5. PRT1419

    Prelude

    Multiple Myeloma

    phase 1 small molecule completed

    1 trial

  6. PRT1419

    Prelude

    Sarcoma

    phase 1 small molecule completed

    1 trial

  7. PRT1419

    Prelude

    Acute Myeloid Leukemia

    phase 1 small molecule terminated

    1 trial

  8. PRT2527

    Prelude

    Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)

    phase 1 small molecule completed

    1 trial

  9. PRT2527

    Prelude

    Sarcoma

    phase 1 small molecule completed

    1 trial

  10. PRT3645

    Prelude

    Breast Cancer

    phase 1 small molecule completed

    1 trial

  11. PRT543

    Prelude

    Relapsed/Refractory Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  12. PRT7732

    Prelude

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  13. PRT811

    Prelude

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

Patents (8)

Search patents →

  1. US 12414953

    Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)

    Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12129262

    CDK inhibitors and their use as pharmaceuticals

    Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11939340

    CDK inhibitors and their use as pharmaceuticals

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11702423

    BRM targeting compounds and associated methods of use

    Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11685744

    CDK inhibitors and their use as pharmaceuticals

    Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11673893

    CDK inhibitors and their use as pharmaceuticals

    Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11622970

    BCL-2 inhibitors and their use as pharmaceuticals

    Expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11524962

    Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5)

    Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Prelude?

Prelude (PRLD) is a pharma company. headquartered in WILMINGTON, DE, USA. listed on NYSE. NovaPharmaNews links 13 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Prelude sponsor?

We track 13 ClinicalTrials.gov-linked programs for Prelude, including KEYTRUDA 25 mg/mL concentrate for solution for infusion, PRT3789 and 12 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Prelude company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.